Adjuvanticity of pGPL-Mc and LRS in the immune responses of monkeys to oral immunization with diphtheria and tetanus toxoids.
Experiments were carried out to examine the adjuvanticity of polar glycopeptidolipids of Mycobacterium chelonae (pGPL-Mc) or the London rocket seed (LRS) when combined with diphtheria and tetanus toxoids in an oral immunization of the African green monkey. The results showed that none of the monkeys receiving diphtheria and tetanus toxoids combined with 25 mg/kg of pGPL-Mc showed an increase in the the level of diphtheria antitoxin (DA) on the third and sixth weeks following the first and the second immunizations. One monkey from this group responded with increased seroneutralizing antibodies 3 weeks after the third feeding. On the other hand, one monkey, 3 weeks after the first immunization, and three monkeys, 3 weeks after the second and third oral vaccinations, showed an increase in specific anti-diphtheria antibody responses when the toxoids were combined with 25 mg/kg of LRS. The anti-diphtheria antitoxin responses of monkeys receiving diphtheria and tetanus toxoids combined with 50 mg/kg of pGPL-Mc or 50 mg/kg of LRS were significantly enhanced compared to the groups administered 25 mg/kg of the two adjuvants. The increase was observed in four out of five pGPL-Mc administered and in three out of five LRS-receiving monkeys. The results show that pGPL-Mc induced the highest titres of anti-diphtheria antitoxin compared to LRS, whereas the level of anti-diphtheria antitoxin titre of the two monkeys receiving the toxoids alone was less than 0.1 i.u./ml of serum throughout the experiment. According to the statistical analyses, no significant differences were recorded between the diphtheria antitoxin responses of monkeys following the first, second or third administration of LRS-adjuvated diphtheria and tetanus toxoids. However, a significant difference (P < or = 0.05) was observed in the diphtheria antitoxin response between the first and the second immunization of monkeys administered with toxoids adjuvated with 50 mg/kg of pGPL-Mc. The tetanus antitoxin responses of all monkeys were less than 0.1 i.u. of antitoxin per millilitre of serum throughout the study, which is considered not to be protective. However, we have recorded an anti-tetanus antitoxin titre of more than 0.2 i.u./ml of serum in one monkey that received diphtheria and tetanus toxoids combined with 50 mg/kg of pGPL-Mc.
Mirchamsy
H
H
Razi State Serum and Vaccine Institute, Tehran, Islamic Republic of Iran.
Neway
T
T
Hamedi
M
M
Pilet
C
C
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000284:Administration, Oral; D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology; D002214:Capsules; D002522:Chlorocebus aethiops; D004165:Diphtheria / Q000276:immunology* / Q000517:prevention & control*; D004166:Diphtheria Antitoxin / Q000032:analysis / Q000097:blood; D004168:Diphtheria Toxoid / Q000008:administration & dosage / Q000276:immunology*; D004337:Drug Carriers; D016503:Drug Delivery Systems / Q000379:methods; D008081:Liposomes; D016926:Mycobacterium chelonae / Q000276:immunology; D009500:Neutralization Tests; D012639:Seeds / Q000276:immunology; D017693:Sodium Bicarbonate / Q000494:pharmacology; D013742:Tetanus / Q000276:immunology* / Q000517:prevention & control*; D013743:Tetanus Antitoxin / Q000032:analysis / Q000097:blood; D013745:Tetanus Toxoid / Q000008:administration & dosage / Q000276:immunology*; D014611:Vaccination / Q000379:methods*; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D002214:Capsules; D004166:Diphtheria Antitoxin; D004168:Diphtheria Toxoid; D004337:Drug Carriers; D008081:Liposomes; D013743:Tetanus Antitoxin; D013745:Tetanus Toxoid; D017778:Vaccines, Combined; D017693:Sodium Bicarbonate